Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning

Review Oncology

Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review

Sara Steffanoni et al.

Summary: Primary central nervous system lymphoma (PCNSL) requires specific therapeutic strategies. High-dose chemotherapy followed by autologous stem-cell transplantation (HDC/ASCT) has shown effectiveness and safety in PCNSL patients. This review highlights the change in conditioning regimens over time and the optimization of outcomes through improved knowledge of CNS bio-availability and efficacy of chemotherapy agents.

CANCERS (2023)

添加到收藏夹

Review Oncology

Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis

Narendranath Epperla et al.

Summary: The optimal consolidation strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) remains controversial between autologous hematopoietic cell transplant (auto-HCT) and whole-brain radiotherapy (WBRT). A systematic review and meta-analysis of randomized controlled trials was conducted, revealing no significant differences in survival outcomes between auto-HCT and WBRT consolidation, but a higher degree of neurocognitive decline associated with WBRT. Individualized decision-making based on age, frailty, and co-morbidities is recommended.

HEMATOLOGICAL ONCOLOGY (2023)

添加到收藏夹

Article Hematology

Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience

Lauren D. Curry et al.

Summary: Primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) have different characteristics and outcomes. PCNSL occurs primarily in older patients and has a better prognosis, while SCNSL can occur concomitantly with systemic lymphoma or later at relapse and generally has a worse prognosis. The treatment strategies for both types are also different.

ANNALS OF HEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Andres J. M. Ferreri et al.

Summary: This study reported the results of a trial involving 219 HIV-negative adults with primary CNS lymphoma (PCNSL). The results showed that MATRix significantly improves outcome in patients with PCNSL, with a long-term overall survival rate of 21%-56%. Addition of rituximab benefits patients, and the efficacy of whole-brain irradiation and autologous transplantation is comparable. Salvage therapy was ineffective. Importantly, MATRix and ASCT did not increase non-relapse mortality or second tumor incidence, and the side effects differed between WBRT and ASCT.

LEUKEMIA (2022)

添加到收藏夹

Meeting Abstract Hematology

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Gerald Illerhaus et al.

BLOOD (2022)

添加到收藏夹

Article Oncology

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant

Michael Scordo et al.

Summary: In this cohort study, thiotepa-based conditioning regimen was associated with higher rates of survival compared with BEAM, despite higher rates of early toxic effects and NRM. These findings may assist clinicians in choosing between TBC or TT-BCNU based on patient and disease characteristics.

JAMA ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology